尿液前列腺癌基因(PCA3)联合多参数磁共振对前列腺癌的诊断价值

A pilot study on urinary PCA3 combined with multiparametric MRI for the diagnosis of prostate cancer

目的探讨尿液前列腺癌基因3(PCA3)联合多参数磁共振(mpMRI)对前列腺癌的诊断价值。方法以前列腺活检病理结果为金标准,选取40例前列腺癌患者和28例前列腺增生患者为研究对象,采用RT-PCR检测尿液PCA3表达水平,应用受试者操作特性(ROC)曲线分析尿液PCA3、mpMRI及两者联合对前列腺癌的诊断效能。结果前列腺癌组和前列腺增生组尿液PCA3表达量分别为(6.25±1.21)copies/ml和(2.26±0.95)copies/ml(P<0.001);尿液PCA3、mMRI及两者联合诊断前列腺癌的曲线下面积分别为0.693(95%CI:0.569~0.799),0.720(95%CI:0.598~0.822)和0.830(95%CI:0.719~0.910)。结论尿液PCA3联合mMRI对前列腺癌诊断具有较好的临床价值。

Objective To investigate the diagnostic value of urinary prostate cancer gene 3(PCA3)combined with multiparametric MRI(mpMRI)in prostate cancer.Methods RT-PCR was used to detect the expression level of urinary PCA3 of 40 patients with prostate cancer and 28 patients with benign prostatic hyperplasia.The receiver operating characteristic(ROC)curves was constructed to analyze the sensitivity and specificity of urinary PCA3,mpMRI and the combination of them for the diagnosis of prostate cancer.Results The expression level of urinary PCA3 in benign prostatic hyperplasia was lower than that in prostate cancer[(2.26±0.95)copies/ml vs(6.25±1.21)copies/ml,P<0.001].The area under ROC for PCA3,mpMRI,and the combination were 0.693(95%CI:0.569-0.799),0.720(95%CI:0.598-0.822),and 0.830(95%CI:0.719-0.910),respectively.Conclusions The determination of urinary PCA3 combined with mpMRI was valuable biomarker for the diagnosis of prostate cancer.